Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;   High Risk Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Myelodysplastic Syndrome Interventions:   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Drug: Quizartinib Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials